GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Debt-to-Equity

Neogen (NAS:NEOG) Debt-to-Equity

: 0.28 (As of Feb. 2024)
View and export this data going back to 1989. Start your Free Trial

Neogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $2.5 Mil. Neogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $887.7 Mil. Neogen's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $3,146.2 Mil. Neogen's debt to equity for the quarter that ended in Feb. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neogen's Debt-to-Equity or its related term are showing as below:

NEOG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28   Med: 0.28   Max: 0.3
Current: 0.28

During the past 13 years, the highest Debt-to-Equity Ratio of Neogen was 0.30. The lowest was 0.28. And the median was 0.28.

NEOG's Debt-to-Equity is ranked worse than
54.31% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs NEOG: 0.28

Neogen Debt-to-Equity Historical Data

The historical data trend for Neogen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.28

Neogen Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.28 0.28 0.28

Competitive Comparison

For the Diagnostics & Research subindustry, Neogen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neogen's Debt-to-Equity falls into.



Neogen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neogen's Debt to Equity Ratio for the fiscal year that ended in May. 2023 is calculated as

Neogen's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen  (NAS:NEOG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Neogen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neogen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Neogen (NAS:NEOG) Business Description

Traded in Other Exchanges
Address
620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.
Executives
William T Boehm director
Douglas Edward Jones officer: Vice President, CCO 620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly officer: Vice President 620 LESHER PLACE, LANSING MI 48912
James P Tobin director 620 LESHER PLACE, LANSING MI 48895
David H. Naemura officer: VP & CFO C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin officer: Chief Legal & Reg. Officer 620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan officer: VP & CFO 620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta director C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent officer: Chief Executive Officer 822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter director 620 LESHER PLACE, LANSING MI 48912
Ronald D Green director 620 LESHER PLACE, LANSING MI 48912
James C Borel director 1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical officer: General Manager
G Bruce Papesh director 726 APPLEGATE LANE, EAST LANSING MI 48823